SCHEMBL3977031

SCHEMBL3977031

Nc1ncnc2scc(-c3ccc4ccc(-c5ccccc5)nc4n3)c12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.67
RET P07949 4/20 0.67
FGFR1 P11362 4/20 0.67
FLT1 P17948 4/20 0.67
MAP4K4 O95819 4/20 0.67
LCK P06239 4/20 0.67
MET P08581 4/20 0.67
CLK2 P49760 4/20 0.67
MAP4K2 Q12851 4/20 0.67
NTRK3 Q16288 4/20 0.67
CLK4 Q9HAZ1 4/20 0.67
ABL1 P00519 3/20 0.67
NTRK1 P04629 3/20 0.67
CSF1R P07333 3/20 0.67
RPS6KA3 P51812 3/20 0.67
ROCK1 Q13464 3/20 0.67
DYRK1A Q13627 3/20 0.67
NTRK2 Q16620 3/20 0.67
TAOK1 Q7L7X3 3/20 0.67
PDGFRB P09619 3/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3976145 0.83 RET (0.57) KDRRETFGFR1FLT1MAP4K4
SCHEMBL3980106 0.82 KDR (0.66) KDRRETFGFR1FLT1MAP4K4
SCHEMBL3978833 0.82 KDR (0.62) KDRRETFGFR1FLT1MAP4K4
SCHEMBL14013968 0.81 FGFR1 (1.00) KDRRETFGFR1FLT1MAP4K4
SCHEMBL3980294 0.80 KDR (0.52) KDRRETFGFR1FLT1MAP4K4
SCHEMBL3982004 0.78 KDR (0.52) KDRRETFGFR1FLT1MAP4K4
SCHEMBL3979887 0.73 KDR (0.67) KDRRETFGFR1FLT1MAP4K4
SCHEMBL3980829 0.72 KDR (0.62) KDRRETFGFR1FLT1MAP4K4
SCHEMBL3982214 0.71 KDR (0.54) KDRRETFGFR1FLT1MAP4K4
SCHEMBL3977506 0.71 KDR (0.59) KDRRETFGFR1FLT1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566721-B2 Substituted thienol[2,3-d]pyrimidines as kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-07-28 US claimed
EP-2051982-A1 6,6-BICYCLIC RING SUBSTITUTED SULFUR CONTAINING HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2009-04-29 EP claimed
WO-2008018881-A1 6,6-BICYCLIC RING SUBSTITUTED SULFUR CONTAINING HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2008-02-14 WO claimed
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC., 2007-02-08 US claimed
US-7566721-B2 Substituted thienol[2,3-d]pyrimidines as kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032512-A1 6,6-Bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors IGF1R, BRCA1, MAP2K6 KDR 2130/4885RET 1252/4885FGFR1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.